Remepy
Develops Hybrid Drugs combining prescription medicines with AI-driven therapeutic apps
$36MSeries A
Role not disclosedOV
O.G. Venture Partners
Activity from announced rounds
Activity in this selectionOct 24, 2026 · Biotech · Jul 27, 2026
O.G. Venture Partners is the investment firm identified in its own Neko and Buildots materials and by Remepy, which names managing partner Ziv Kop.
Recorded funding activity
Neko combines body scans and bloodwork for preventive assessment. Buildots analyzes construction progress, while Remepy combines medicines with therapeutic applications. The manager retains an identity separate from co-investors and similarly named firms.
Sources
- Rounds participated in
- 1
- Confirmed lead rounds
- — 1 roles undisclosed
- New companies
- 1 First participation on record · 0 follow-on
- Funding in participating rounds
- $36M 1 disclosed · full round size, not this investor’s share